trending Market Intelligence /marketintelligence/en/news-insights/trending/Kc2w25FQxSL-pwDAhojOzw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Vaccinex raises $13.8M from private placement to fund drug program

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Vaccinex raises $13.8M from private placement to fund drug program

Vaccinex Inc. raised $13.8 million via a private placement of 3,382,332 common shares at $4.08 apiece.

Existing shareholders FCMI Parent Co. and Vaccinex (Rochester) LLC are the lead investors in the placement. Vaccinex also entered into a registration rights agreement with the investors in the private placement.

The offering closed July 30 and has no warrants, derivatives or financial covenants associated with it.

The Rochester, N.Y.-based biotechnology company plans to use the additional funding for the ongoing development of its lead drug candidate pepinemab to treat cancer and Huntington's disease, an inherited neurodegenerative disease. The funds would also be used for working capital and general corporate purposes.

Vaccinex transferred its listing from Nasdaq Global Market to Nasdaq Capital Market on July 22 due to platform's lower listing requirements.